
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer ...
Background Abemaciclib in combination with endocrine therapy (ET) is approved for adjuvant treatment of adult patients with hormone receptor–positive/HER2-negative (HR+/HER2–), node-positive, early breast cancer at high risk of recurrence. This …